Gamida Cell - Cell and Immune Therapy Technologies _Shopping

Committed to CuresPioneering next-generation cell therapies for patients with cancer and other serious diseasesContactCareersWho We AreOur R&DPatients & FamiliesPatient Voices: Stacey KhouryPatient Voices: Wayne AltenberndHealthcare ProfessionalsInvestors & MediaOverviewNews & EventsPress ReleasesEvents & PresentationsIn the NewsStock InformationStock Quote & ChartHistorical Price LookupInvestment CalculatorAnalyst CoverageFinancials & FilingsSEC FilingsCorporate GovernanceBoard of DirectorsLeadership TeamCommittee CompositionDocuments & ChartersInvestor ResourcesInvestor ContactsEmail AlertsWho We AreOur R&DPatients & FamiliesHealthcare ProfessionalsInvestors & MediaOverviewNews & EventsPress ReleasesEvents & PresentationsIn the NewsStock InformationStock Quote & ChartHistorical Price LookupInvestment CalculatorAnalyst CoverageFinancials & FilingsSEC FilingsCorporate GovernanceBoard of DirectorsLeadership TeamCommittee CompositionDocuments & ChartersInvestor ResourcesInvestor ContactsEmail AlertsContactCareersLatest NewsView AllMay 03, 2022Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and WebcastRead MoreApr 27, 2022Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsRead MoreApr 26, 2022Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201Read MoreApr 25, 2022Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsRead MoreApr 25, 2022Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsRead MoreApr 07, 2022Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare ConferenceRead MoreMar 15, 2022Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company UpdateRead MoreMar 10, 2022Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare ConferenceRead MoreMar 08, 2022Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and WebcastRead MoreFeb 09, 2022Gamida Cell Initiates Rolling Submission of Biologics License Application for OmidubicelRead MoreJan 31, 2022Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of DirectorsRead MoreJan 31, 2022Gamida Cell Provides Key Program Updates and 2022 Financial GuidanceRead MoreJan 19, 2022Gamida Cell Provides Update on Omidubicel BLA SubmissionRead MoreJan 07, 2022Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsRead MoreDec 13, 2021Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual MeetingRead MoreDec 11, 2021Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual MeetingRead MoreNov 16, 2021Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor ConferencesRead MoreNov 15, 2021Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company UpdateRead MoreNov 11, 2021Gamida Cell Provides Update on Pre-BLA Meeting With FDA for OmidubicelRead MoreNov 09, 2021Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingRead MoreNov 08, 2021Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and WebcastRead MoreNov 04, 2021Gamida Cell Announces Data to Be Presented at 63rd ASH Annual MeetingRead MoreNov 04, 2021Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) EuropeRead MoreOct 26, 2021Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D DayRead MoreOct 19, 2021Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingRead MoreSep 28, 2021Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy PipelineRead MoreSep 02, 2021Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in SeptemberRead MoreAug 11, 2021Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company UpdateRead MoreAug 04, 2021Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and WebcastRead MoreAug 03, 2021Gamida Cell to Present at the BTIG Virtual Biotechnology ConferenceRead MoreJun 23, 2021Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell TransplantRead MoreJun 09, 2021Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in JuneRead MoreJun 07, 2021Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing UpdateRead MoreMay 12, 2021Gamida Cell to Present at the RBC Capital Markets Global Healthcare ConferenceRead MoreMay 11, 2021Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company UpdateRead MoreMay 04, 2021Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and WebcastRead MoreApr 07, 2021Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare ConferenceRead MoreMar 15, 2021Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)Read MoreMar 09, 2021Gamida Cell Reports Full Year 2020 Financial Results and Provides Company UpdateRead MoreMar 03, 2021Gamida Cell to Present at Upcoming Investor ConferencesRead MoreMar 02, 2021Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and WebcastRead MoreMar 01, 2021Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)Read MoreFeb 16, 2021Gamida Cell Announces $75 Million Financing with Highbridge Capital ManagementRead MoreFeb 09, 2021Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTRRead MoreJan 11, 2021Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTRRead MoreJan 05, 2021Gamida Cell to Present at Upcoming January Investor ConferencesRead MoreDec 21, 2020Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesRead MoreDec 18, 2020Gamida Cell Added to NASDAQ Biotechnology IndexRead MoreDec 17, 2020Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary SharesRead MoreDec 16, 2020Gamida Cell Announces Launch of Public Offering of Ordinary SharesRead MoreDec 14, 2020Gamida Cell Provides Regulatory Update on Biologics License Application for OmidubicelRead MoreDec 09, 2020Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020Read MoreDec 05, 2020Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and ExpositionRead MoreDec 02, 2020Gamida Cell to Host Virtual Pipeline Deep DiveRead MoreNov 24, 2020Gamida Cell to Present at Upcoming ConferencesRead MoreNov 10, 2020Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company UpdateRead MoreNov 04, 2020Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual MeetingRead MoreNov 04, 2020Gamida Cell to Present at H.C. Wainwright 6th Annual Israel ConferenceRead MoreNov 02, 2020Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and WebcastRead MoreOct 13, 2020Gamida Cell and Be The Match BioTherapies® Expand Strategic CollaborationRead MoreOct 07, 2020Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the MesaRead MoreOct 06, 2020Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic MalignanciesRead MoreSep 10, 2020Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect MeetingRead MoreSep 08, 2020Gamida Cell to Participate in Upcoming Investor ConferencesRead MoreSep 03, 2020Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in SeptemberRead MoreAug 17, 2020Gamida Cell to Provide Webcast of Its Annual Meeting of StockholdersRead MoreAug 11, 2020Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company UpdateRead MoreAug 04, 2020Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and WebcastRead MoreJul 21, 2020Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial OfficerRead MoreJul 07, 2020Gamida Cell Announces Appointment of David Fox to Its Board of DirectorsRead MoreJun 12, 2020Gamida Cell to Present at the JMP Securities Virtual Hematology and Oncology ForumRead MoreMay 26, 2020Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesRead MoreMay 21, 2020Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company UpdateRead MoreMay 18, 2020Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary SharesRead MoreMay 18, 2020Gamida Cell Announces Launch of Proposed Public Offering of Ordinary SharesRead MoreMay 18, 2020Gamida Cell Announces the Date of Its First Quarter 2020 Financial Results and WebcastRead MoreMay 12, 2020Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic MalignanciesRead MoreMar 02, 2020Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow TransplantationRead MoreFeb 25, 2020Gamida Cell Reports Full Year 2019 Financial Results and Provides Company UpdateRead MoreFeb 19, 2020Gamida Cell Announces the Date of Its Full Year 2019 Financial Results and WebcastRead MoreJan 13, 2020Gamida Cell Announces 2020 Goals and Provides Company UpdateRead MoreJan 02, 2020Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of OmidubicelRead MoreDec 09, 2019Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual MeetingRead MoreNov 21, 2019Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare ConferenceRead MoreNov 13, 2019Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company UpdateRead MoreNov 06, 2019Gamida Cell Announces Data to be Presented at ASH 2019 Annual MeetingRead MoreNov 05, 2019Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and WebcastRead MoreSep 11, 2019Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular TherapyRead MoreAug 06, 2019Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company UpdateRead MoreJul 23, 2019Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and WebcastRead MoreJul 08, 2019Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesRead MoreJun 26, 2019Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary SharesRead MoreJun 24, 2019Gamida Cell Announces Launch of Proposed Public Offering of Ordinary SharesRead MoreJun 19, 2019Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for OmidubicelRead MoreJun 05, 2019Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific OfficerRead MoreMay 31, 2019Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual MeetingRead MoreMay 29, 2019Gamida Cell to Hold Annual Meeting of StockholdersRead MoreMay 09, 2019Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York CityRead MoreMay 07, 2019Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company UpdateRead MoreApr 30, 2019Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and WebcastRead More@GAMIDACELLTXFollow Us on Social MediaMay 3, 2022This month, we honor National Cancer Research Month, initiated by @AACR as a time to highlight the importance of life-saving research to the millions of people across the globe affected by cancer. #NCRM22 https://t.co/B5mDJV0dzVApril 27, 2022At this year’s #Tandem22 Meetings we highlighted GDA-201, our lead NAM-enabled natural killer (NK) cell therapy for the treatment of hematologic and solid tumors. Learn more here: https://t.co/VGOT20vZJs https://t.co/aEQ9RKIYdkApril 27, 2022We presented Phase 3 data on our lead advanced cell therapy candidate, omidubicel, and its advantages of early engraftment and lower infections compared to umbilical cord blood transplantation. Learn more here: https://t.co/uFlZkXEl8p #Tandem22 https://t.co/KEUvHnyX6xPatient focusThe needs and experiences of patients are at the core of our mission and purpose. Read about one woman’s personal journey through cancer diagnosis, treatment and more than 10 years as a survivor.Meet StaceyFuture of cancer careWe are creating a pipeline of advanced cell therapies designed to deliver a curative approach for patients with cancer.Learn moreDedicated teamWe combine bold and creative pursuits in science with a passion for curing cancer so that patients can live longer, better lives.Meet us © 2022 Gamida CellPrivacy PolicyTerms of Use   © 2022 Gamida Cell ×